Clinical Trial: Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06374043) titled 'Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin' on April 15.

Brief Summary: Randomized placebo-controlled double-blind cross-over N=1 trial in adult male and female patients with UACR >20 mg/g (2.26 mg/mmol) with type 2 diabetes treated in primary or secondary healthcare.

The goal of this clinical trial is to determine the individual response to the SGLT2 inhibitor dapagliflozin in urine albumin-to-creatinine ratio (UACR). Secondary objectives are to determine the individual response to dapagliflozin in systolic blood pressure, body weight, eGFR, and fasting plasma glucose.

P...